Upper urinary tract urothelial carcinoma (UUT-UC) is an uncommon disease. Radical nephroureterectomy (NU) is the standard of care for invasive, nonmetastatic UUT-UC. However, UUT-UC is a biologically aggressive malignancy with the potential for disease recurrence and cancer-specific mortality (CSM). The pathological T and N categories and pathologically defined tumour grade are powerful indicators of prognosis. Several other postoperative prognostic risk factors have been identified to help in the clinical decision-making for optimal management.

Improved risk stratification and accurate individualised prediction of postoperative survival outcomes can help guide patient counseling, follow-up scheduling, administration of adjuvant therapies, and design of clinical trials ([@bib2]). Decision aids, such as risk groupings, probability tables, neural networks, and nomograms, have greatly enhanced the ability to predict outcomes. Among the available decision aids, nomograms are the most accurate and discriminatory tools for predicting outcomes in patients with UC ([@bib22]). In contrast to models that assign prognosis based on risk groups, nomograms provide prognostic information based on a combination of variables that allow for a more individualised prediction of outcome.

To date, several nomograms have been established to predict disease stage at the time of radical NU ([@bib16]; [@bib5]) or perioperative mortality ([@bib12]) and to predict prognosis for patients after radical NU ([@bib13]; [@bib2]; [@bib20]; [@bib26]). All nomograms consider clinical and/or pathological variables, but they differ with regard to the number and type of covariates and end points. As some nomograms use an obsolete historical tumour grading system ([@bib13]; [@bib2]), they are not useable in a daily clinical environment as one of the four variables. Recently, [@bib26] developed a new nomogram based on the French collaborative national database on UUT-UC to predict 3- and 5-year cancer-specific survival (CSS). This nomogram was developed from a large cohort of 397 patients between 1995 and 2010 at 11 major medical centres throughout France. Performance of this model has been subsequently validated on 270 patients at another 10 institutions in France ([@bib26]). The nomogram uses the recommended World Health Organisation (WHO) grading system for UC, and only this is available as online calculator. Online availability allows easy and unrestricted access by physicians at any institution worldwide, and the calculator tool functions to generate results quickly, facilitating its use in patient counseling and tumour board discussions ([@bib10]).

To our knowledge, validation of Yates nomogram has never been investigated separately for other cohort who underwent radical NU. Despite good performance of the nomogram in a separate data set, concerns related to the generalisability of the nomogram remain. The objective of the current study was to validate the online nomogram using a different cohort.

Materials and methods
=====================

Patient selection
-----------------

This was an institutional review board-approved study before initiation of the study. From October 1991 to October 2010, medical records of patients treated by surgery for UUT-UC at our institution were retrospectively reviewed. We excluded 18 patients treated by segmental resection, 11 patients who underwent previous or concurrent radical cystectomy, 9 patients with distant metastasis before radical NU, 6 patients who received neoadjuvant chemotherapy, 3 patients with non-UC, and 6 patients with incomplete information on patient age, pathological tumour and nodal stage, lymphovascular invasion, concomitant carcinoma *in situ*, neoadjuvant or adjuvant chemotherapy, and radiotherapy status. The study comprised the remaining 328 patients with UUT-UC who underwent open (*n*=251) or laparoscopic (*n*=77) radical NU. The demographic data for nomogram development cohort in comparison to external validation cohort is shown in [Table 1](#tbl1){ref-type="table"}. The hilar and regional lymph nodes adjacent to the ipsilateral great vessel were generally resected if palpable intraoperatively or enlarged on preoperative axial imaging. The extent of lymphadenectomy performed was at the discretion of the individual surgeons.

Pathology review
----------------

All surgical specimens were examined according to the standard pathological procedure at our institution. Pathological specimens were processed and evaluated according to the standard pathological procedures by staff surgical pathologists at our institution. Pathological stage was assigned to the 2002 TNM classification by the American Joint Committee on Cancer-Union for International Cancer Control (AJCC/UICC) ([@bib8]) and tumour grading was assessed according to both the recommended 1973 WHO system and the 1998/2004 International Society of Urological Pathology/WHO consensus classification ([@bib18]; [@bib4]).

Follow-up
---------

Patients were generally followed up after radical NU at least every 3--4 months for the first year and then were followed up semi-annually from the second through the fifth year. After 5 years, patients were seen annually. Follow-up consisted of physical examination, serum chemistry evaluation, urinary cytology, cystoscopic evaluation of the urinary bladder, chest X-rays, renal ultrasound, and/or computed tomography scan. CSM was defined as time from radical NU to death from UUT-UC. Cause of death was determined by chart review, the Korea National Statistical Office, and/or confirmed by interview with the family of the patient. Perioperative mortality was censored at the time of death for CSM analyses.

Online nomogram
---------------

An online version of risk calculator developed by [@bib26] is available at <http://labs.fccc.edu/nomograms/nomogram.php?id=66&audience=1>. The nomogram requires tumour location (coded as renal pelvis=1, ureter=2, and ureter and renal pelvis=3), tumour grade (coded as 1=1, 2=2, and 3=3), age (incorporated as continuous variables from 20 to 100), pT stage (coded as pTa=1, pT1/CIS=2, pT2=3, and pT3/4=4), and pN stage (coded as pN0/x=1 and pN+=2). Each patient was tested with the 'on-line tool\'. After data were entered, the software calculated the probability of CSM at 3 and 5 years after radical NU.

Statistical analysis
--------------------

Multivariate survival analysis with calculation of hazard ratio (HR) with 95% confidence interval (CI) was performed using the Cox proportional hazards model including all covariates that were significant on univariate analysis. Competing risk regression analysis was also performed by calculating the cumulative incidence function.

The predicted risk of CSM was compared with the actual CSM in the current study population at 3 and 5 years. The discrimination of models was quantified using Harrell\'s concordance index ([@bib9]), which is similar to the area under the curve for receiver operating characteristics curve but allows calculation in continuous and censored data (such as time to event data). Harrell\'s concordance index is a measure of how well a tool can determine the relative risk of individual patients in the population sample. A value of 1.0 indicates perfect predictions, whereas 0.5 is equivalent to a toss of a coin.

Calibration reflects how well the tool predicts an absolute outcome, such as the likelihood of survival at 3 and 5 years. The relationship between the model-derived and actuarial CSM was graphically explored within calibration plots to explore nomogram performance. External validation was done using 200 bootstrap resamples to decrease overfit bias. Calibration was also assessed using the quartiles of the predicted survival at 3 and 5 years and calculation of the corresponding observed Kaplan--Meier estimates. To determine the net benefit derived by examining the theoretical relation between the threshold probability of developing an event and the relative value of false-positive and false-negative results, we relied on decision curve analysis ([@bib25].

For all the statistical tests, two-sided *P*\<0.05 was considered statistically significant. Statistical calculations were performed using SPSS v.18.0 (SPSS, Chicago, IL, USA) and R package, v.2.6.1 (<http://www.R-project.org>).

Results
=======

Age, tumour location, bladder cuff removal, pathological T category, pathological N category, tumour grade, and positive surgical margin were associated with CSS on univariate analysis while sex and associated CIS were not. On multivariate analysis, age (*c* index=0.569), tumour location (*c* index=0.572), bladder cuff removal (*c* index=0.603), pathological T category (*c* index=0.727), and positive surgical margin (*c* index=0.546) retained independent association with CSS ([Table 2](#tbl2){ref-type="table"}).

[Figure 1](#fig1){ref-type="fig"} shows the CSS adjusted for the competing risk of death from other causes. The risk of dying from UUT-UC outweighed the risk of dying from other causes.

The discrimination accuracy of the nomograms at 3 and 5 years was 74.2% and 74.2%, respectively. To assess the agreement between the predicted and actual outcomes, we generated calibration curves. The dashed line represents the performance of an ideal nomogram, where the predicted outcome would correspond perfectly with the actual outcome. The performance of nomogram is plotted as the solid line. The solid line is not close to the dashed line in the ideal nomogram. The calibration plots tend to exaggerate the overestimation of mortality between predicted and observed probabilities at 3 and 5 years for survival ([Figure 2](#fig2){ref-type="fig"}).

[Figure 3](#fig3){ref-type="fig"} illustrates the Kaplan--Meier curves for patients stratified into four groups from the nomograms. Patients were clustered into four groups according to their nomogram-predicted survival (first quartile, \<25% second quartile, 25--50% third quartile, 50--75% and fourth quartile, \>75%). As depicted, models discriminated well, and log-rank tests were all highly significant.

[Figure 4](#fig4){ref-type="fig"} presents the results of the decision curve analysis at 3 and 5 years. Decision curve analysis revealed that the use of nomograms was associated with net benefit gains relative to the treat-all strategy. When compared with AJCC/UICC staging system, the nomograms performed well across a wide range of threshold probabilities using the decision curve analysis.

The advantage of the combined prognostic factors expressed through the nomogram over the AJCC/UICC staging system is shown in [Figure 5](#fig5){ref-type="fig"}. The heterogeneity was found particularly in higher stages.

Discussion
==========

The outcomes of patients with UUT-UC after radical NU are heterogeneous and difficult to predict. Predictive models may help clinicians to plan treatments and to better inform patients about the options and potential consequences of therapies. The clinician\'s ability to predict a given clinical outcome is less accurate than the mathematically-based models. Given the relative rarity of UUT-UC, data regarding clinicopathological predictors of outcomes are sparse.

Although risk grouping is a logical approach, grouping patients is an inefficient use of the data and tends to reduce the predictive accuracy of a prognostic model (spectrum bias; [@bib23]). The misconception related to this approach is that it assumes that all patients within a risk group are equal. In addition, risk grouping requires the conversion of continuous to categorical variables, which limits information about the actual value. In contrast to risk groups, a nomogram provides an individualised estimate of the predicted probability of the event of interest, which is entirely based on the individual\'s disease characteristics, without averaging or combining within a category ([@bib23]). The principle advantage of nomogram is that it provides a survival probability for individual cases.

Some nomograms addressing the outcomes for patients who received radical NU have been introduced ([@bib13]; [@bib2]; [@bib20]; [@bib26]). These tools exceed AJCC/TNM staging for prognosis of survival in internal validation. However, further external validation of the current nomograms in other independent datasets, preferably from different countries or races, should be performed, as differences in population characteristics and treatment may undermine the accuracy and calibration of nomograms. Regarding prediction of CSS with the online nomogram developed by [@bib26], predictive accuracy has been previously examined; in internal validation, the concordance index *c* was 0.78.

The aim of the present study was to externally validate the previously developed nomogram in the prediction of CSM in a different patient cohort who had undergone radical NU for UUT-UC. To our knowledge, this is the first study to validate the prognostic models for UUT-UC based on a population other than Caucasian. We have observed a good prediction of clinical outcome by the nomogram. The accuracies of 3- and 5-year nomograms were both 74.2%. Although the Kaplan--Meier curve is within the boundaries of 3- and 5-year predictions for each of the four strata, the correspondence seen between the actual and ideal nomogram predictions by the calibration plot does not suggest good calibration of the nomogram in the validation cohort. The predictive model may be impaired due to the impact of an uneven distribution of unknown risk modifying characteristics between the derivation and validation cohort. Therefore, heterogeneity in patient populations (e.g., ethnicity, genetic background, and specific distribution of risk factors) or differences in hospital- and physician-specific treatment strategies and follow-up protocols can lead to poor calibration in comparison with the derivation cohort ([@bib19]). Using DCA, the nomogram demonstrated better net benefit gains relative to the AJCC/TNM staging system for predictions of the examined end points at 3 and 5 years after radical NU. As depicted in [Figure 4](#fig4){ref-type="fig"}, nomogram predictions differ a lot within stages, especially higher stages. As nomogram discrimination was significantly superior to that of UICC/AJCC stage grouping, it may be suggested that survival, especially for patients with high-stage tumours, is influenced by factors that are not included in the UICC/AJCC classification.

Undoubtedly, further improvements in predictive models can also be attained by incorporating established risk factors. For example, the Yates nomogram is only for use in patients with urothelial carcinoma and not suitable for other subtypes like squamous cell carcinoma. Also, this nomogram do not include risk factors that have shown to correlate significantly with the clinical outcome of patients, including bladder tumour history ([@bib17]), preoperative hydronephrosis grade ([@bib11]), tumour multifocality ([@bib3]), lymphovascular invasion ([@bib1]; [@bib15]; [@bib7]), tumour architecture ([@bib6]), and tumour necrosis ([@bib14]; [@bib28]). [@bib2] and [@bib20] developed the prognostic models and confirmed the importance of lymphovascular invasion and tumour architecture, two strong prognostic variables that have been associated with features of biologically and clinically aggressive UUT-UC.

Combinations of molecular markers improve the prediction of recurrence and survival in patients with advanced urothelial carcinoma of the bladder (pT3-4 or N+) ([@bib21]) as well as organ-confined disease (pT1-2N0M0) ([@bib27]). Therefore, novel biomarkers should be implemented into future prediction models to provide more individualised risk estimations. The ability of biomarker data has been confirmed to improve nomogram predictions ([@bib24]). However, the limited availability of such molecular markers might restrict the widespread application of such models. In addition, as racial differences may also exist in the expression of molecular markers, validation of these models should be performed in the following research, including different races.

Several limitations of this study merit discussion. First, the retrospective design of this study includes patient data that were retrieved over two decades. We excluded six patients without complete clinical information or whose pathologies were not available, thus introducing a possible selection bias. Second, nomogram prediction is not 100% accurate. This limitation is shared with all the other prediction tools. Differences between the two patient cohorts exist, which may be considered as potential limitations. For example, the validation cohort was more likely to have higher pathological T category and lower tumour grade than the nomogram-development cohort. This fact may influence our results. In addition, the duration of follow-up in the validation cohort was longer than that in the nomogram-development population. Late events (or the absence of late events) occurring when patients were censored would be capable of influencing the survival rates in such a population overproportionally. This may also explain the reason why the predictions calculated using the nomogram are linked with a better prognosis than the actual outcome. Third, it is worrisome that 18.6% of patients did not undergo a bladder cuff excision, which represents a standard of care in patients with a radical NU. Lack of removal of the distal ureter and ureteral orifice may predispose a patient to local recurrences. Finally, lack of lymph node dissection standardisation represents another concern. The extent of lymph node dissection is not standardised in UUT-UC. In the present study, 83.2% of patients were not staged with a lymph node dissection. As it may underestimate the proportion of patients with lymph node metastases, this could explain the overestimation of the survival in the validation cohort.

Conclusions
===========

Risk stratification based on current AJCC/TNM staging suffers from significant heterogeneity within each staging group. The online nomogram developed based on the French collaborative national database on UUT-UC is a highly accurate prognostic tool for patients with UUT-UC treated with radical NU. The model can provide an accurate estimate of the individual risk of CSM and outperformed the use of the AJCC/TNM-based predictions with regard to the net benefit. These results encourage the use of this model derived from a European patient cohort for predicting clinical outcome of non-European patients. Nevertheless, further improvements and implementations of novel molecular markers are needed.
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![**Predicted probability of cause-specific cumulative incidence of death from other causes and from upper urinary tract urothelial carcinoma.**](bjc2013462f1){#fig1}

![**Calibration plots depicting the correlation between predicted and actual cancer-specific mortality.** (**A**) Nomogram-predicted probability of 3-year cancer-specific survival. (**B**) Nomogram-predicted probability of 5-year cancer-specific survival. The line containing error bars (95% CI) represents the performance of the models applied to the observed fractions surviving.](bjc2013462f2){#fig2}

![**Patient survival by quartiles of nomograms predictions for (**A**) 3-year cancer-specific survival (*P*\<0.001) and (**B**) 5-year cancer-specific survival (*P*\<0.001) (First quartile \<25% Second quartile, 25--50% Third quartile, 50--75% Fourth quartile, \>75%).**](bjc2013462f3){#fig3}

![**Decision curve analysis for 3-year and 5-year cancer-specific mortality.** (**A**) Nomogram-predicted probability of 3-year cancer-specific survival. (**B**) Nomogram-predicted probability of 5-year cancer-specific survival. In decision curve analysis, the y axis measures net benefit, calculated by summing the benefits (true positives) and subtracting the harms (false positives). The straight line represents the assumption that all patients will die, and the horizontal line represents the assumption that no patients will die. The dotted line indicates the net benefit of using the new model. Model 1 refers to the AJCC/UICC staging system. Model 2 refers to the nomograms.](bjc2013462f4){#fig4}

![**Distribution of nomogram predictions within each AJCC/UICC stage grouping.** (**A**) Nomogram-predicted probability of 3-year cancer-specific survival. (**B**) Nomogram-predicted probability of 5-year cancer-specific survival.](bjc2013462f5){#fig5}

###### Descriptive statistics of development cohort and external validation cohort

                                 **Nomogram development cohort**   **External validation cohort**                        
  ----------------------------- --------------------------------- -------------------------------- --------------------- -------
  **Variable**                         **No. of patients**                     **%**                **No. of patients**   **%**
  No. of patients                              397                              100                         328            100
  **Age, years**                                                                                                         
  Mean                                         68                                                          63.1              
  Range                                      26--100                                                    24.5--90.0           
  **Sex**                                                                                                                
  Male                                         255                              64.2                        261           79.6
  Female                                       142                              35.8                        67            20.4
  **Tumour location**                                                                                                    
  Renal pelvis                                 229                              57.7                        165           50.3
  Ureteral                                     105                              26.4                        118           36.0
  Both synchronously                           63                               15.9                        44            13.4
  **Bladder cuff removal**                     258                               65                         267           81.4
  **Lymph node dissection**                                                                                              
  Yes                                          160                              40.3                        55            16.8
  **Pathological T category**                                                                                            
  pTa/cis                                       0                                0                          49            14.9
  pT1                                          212                              53.4                        77            23.5
  pT2                                          36                                9                          56            17.1
  pT3                                          126                              31.7                        137           41.8
  pT4                                          23                               5.9                          9             2.7
  **Pathological N category**                                                                                            
  pN0                                          122                              30.7                        40            12.2
  pN1-3                                        38                               9.6                         15             4.5
  pNx                                          237                              59.7                        273           83.2
  **Tumour grade**                                                                                                       
  I                                            30                               7.5                         16             4.9
  II                                           155                               39                         215           65.5
  III                                          212                              53.5                        97            29.6
  Associated CIS                               16                                4                          23             3.6
  Positive surgical margin                     27                               6.8                         16             4.9
  **Follow-up, months**                                                                                                  
  Mean                                        33.6                                                         74.8              
  Range                                      0--225                                                     0.1--242.7           

Abbreviation: CIS=carcinoma *in situ.*

###### Univariate and multivariate Cox proportional hazard regression analysis of cancer-specific survival

                                      **Univariate**      **Multivariate**                                          
  ------------------------------ ------------------------ ------------------ ------------- ------------------------ -------------
                                     **HR (95% CI)**      **P-value**        **C index**       **HR (95% CI)**      **P-value**
  Age, years                       1.023 (1.000--1.046)   0.049              0.569           1.029 (1.006--1.054)   0.014
  **Sex**                                                                    0.509                                   
  Male                                  Reference                                                                    
  Female                           1.128 (0.667--1.906)   0.653                                                      
  **Tumour location**                                                        0.572                                   
  Renal pelvis                          Reference                                                 Reference          
  Ureteral                         1.625 (0.991--2.666)   0.054                              1.370 (0.794--2.365)   0.258
  Both synchronously               2.319 (1.279--4.206)   0.006                              2.022 (1.062--3.851)   0.032
  **Bladder cuff removal**                                                   0.603                                   
  Yes                                   Reference                                                 Reference          
  No                               2.668 (1.662--4.283)   \<0.001                            2.754 (1.680--4.514)   \<0.001
  **Pathological T category**                                                0.727                                   
  pTa                                   Reference                                                 Reference          
  pT1/cis                         2.199 (0.457--10.588)   0.326                             2.267 (0.468--10.981)   0.309
  pT2                             7.157 (1.636--31.299)   0.009                             6.020 (1.337--27.120)   0.019
  pT3/4                           12.861 (3.137--52.723)  \<0.001                           10.962 (2.598--46.257)  0.001
  **Pathological N category**                                                0.527                                   
  pN0/x                                 Reference                                                 Reference          
  pN+                              2.422 (1.115--5.264)   0.025                              1.244 (0.515--3.004)   0.627
  **Tumour grade**                                                           0.604                                   
  I                                     Reference                                                 Reference          
  II                               2.124 (0.514--8.786)   0.298                              1.976 (0.433--9.026)   0.379
  III                             4.491 (1.080--18.676)   0.039                             2.330 (0.489--11.115)   0.288
  **Associated CIS**                                                         0.507                                   
  No                                    Reference                                                                    
  Yes                              1.334 (0.614--2.900)   0.467                                                      
  **Positive surgical margin**                                               0.546                                   
  Negative                              Reference                                                 Reference          
  Positive                         4.109 (1.973--8.556)   \<0.001                            2.323 (1.081--4.993)   0.031

Abbreviations: CI=confidence interval; CIS=carcinoma *in situ*; HR=hazard ratio.
